CJ Bioscience announced on June 26 that it unveiled its groundbreaking integrated platform technology in the field of gut microbiome-based precision nutrition at the Korean Society for Microbial Biotechnology (KMB) Conference, held over three days from June 24 to 26.


The core of this announcement is that CJ Bioscience has completed a 'full-cycle integrated platform' that goes beyond simply reading and analyzing the composition of the gut microbiome. This platform enables a precise understanding of an individual's gut ecosystem and allows for high-fidelity simulation and verification in the lab of how specific substances induce changes in the gut environment.

Lee Jaehee, Head of the Wellness Research Group, is giving a session presentation at the Korean Society for Microbial Biotechnology Conference held on the 24th. CJ Bioscience

Lee Jaehee, Head of the Wellness Research Group, is giving a session presentation at the Korean Society for Microbial Biotechnology Conference held on the 24th. CJ Bioscience

View original image

To achieve this, CJ Bioscience utilized its proprietary precision analysis platform, 'Ez-Mx,' to analyze gut microbiome data from healthy Koreans at high resolution. This technology enables identification of microbes at the species level at about three times the rate of public databases. Using this, researchers subdivided Korean gut microbiome types from three to six categories and provided a detailed interpretation of individual gut environments. Furthermore, by using representative samples of each type, they built the patented gut-mimicking platform 'DIGEST,' which allows for perfect ex vivo reproduction of human digestive processes and gut microbial environments, as well as high-throughput screening of beneficial microbial metabolites. The newly introduced 'DIGEST-Flow' system makes it possible to continuously monitor real-time changes in microbial communities under dynamic gut flow conditions.


The most noteworthy aspect is that the core results of these ex vivo experiments were replicated in actual human subjects. In a clinical trial involving 186 participants with complex dietary interventions, the microbial change patterns predicted by the DIGEST system were consistently observed in human clinical data. Through this large-scale clinical study, an increase in gut microbiome diversity and the quantitative proliferation of key beneficial bacteria such as Faecalibacterium and Bifidobacterium were demonstrated. By integrating a machine learning-based responsiveness prediction model, the technology was further advanced to the point where it can predict in advance which individuals a particular solution will be effective for.


While conventional services in the microbiome industry have generally been limited to 'recommending' products by simply observing the state of the microbiome at a specific time point, CJ Bioscience is being recognized for building a unique technological barrier that connects ex vivo experiments, human clinical validation, and AI prediction in one seamless process.


A CJ Bioscience official stated, "The key strength of this platform is that it is not just a recommendation model, but a 'validation platform' capable of pre-verifying the actual effectiveness of specific foods or nutrients and predicting individual responsiveness. We expect this will set a new standard for precision healthcare not only in gut health management but also in areas such as mitigating side effects of obesity drugs (GLP-1) and metabolic diseases."



Meanwhile, at this conference, CJ Bioscience also presented the results of its research on the gut colonization-based mechanism of action for its microbiome drug candidate 'CJRB-201.' Through host transcriptome analysis (Host RNA-seq), the study confirmed that 'CJRB-201' colonization induced gene expression responses related to gut barrier restoration, such as mucus barrier regulation, energy metabolism of intestinal epithelial cells, and recovery and proliferation of epithelial cells. Additionally, in animal models, 'CJRB-201' demonstrated outstanding therapeutic efficacy, including weight loss and improvement of inflammation markers and tissue damage, thereby solidifying a differentiated rationale for new drug development linking gut colonization-based metabolite production and host intestinal epithelial response.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing